Schedule I Controlled Substances: Criteria, Examples, and Penalties

Schedule I controlled substances are the drugs the federal government treats most harshly under the Controlled Substances Act: substances found to have a high potential for abuse, no accepted medical use in the United States, and no way to be used safely even under a doctor’s supervision. Heroin, LSD, psilocybin, peyote, MDMA, and most forms of marijuana all sit in this category. The classification carries the steepest criminal penalties in the drug code, bars the substance from being prescribed, and forces anyone who wants to study it through a demanding federal registration process.

The Three Findings That Define Schedule I

Federal law spells out three findings that must all be satisfied before a substance can be placed in Schedule I. Under 21 U.S.C. § 812(b)(1), the government must determine that the substance has:

A high potential for abuse;
No currently accepted medical use in treatment in the United States; and
A lack of accepted safety for use under medical supervision.

All three prongs have to be met. A drug with a high abuse potential but a recognized medical application falls into Schedule II instead. Fentanyl and methamphetamine, for example, both have narrow but approved medical uses, so they sit in Schedule II rather than Schedule I. The three-prong test is what separates Schedule I from every other tier in the system.¹

The scientific side of the analysis is not left to the DEA alone. Before scheduling or descheduling any substance, the Attorney General must request a scientific and medical evaluation from the Secretary of Health and Human Services, carried out through the FDA. The Secretary’s conclusions on medical and scientific questions bind the Attorney General. If HHS concludes a substance should not be controlled, the DEA cannot schedule it anyway.²

Examples of Schedule I Drugs

Heroin

Heroin is the textbook Schedule I narcotic. It appears on the statute’s own list of controlled opium derivatives and functions as the benchmark for high-abuse-potential drugs with no medical application.¹

LSD, Psilocybin, and Peyote

LSD, psilocybin (the active compound in certain mushrooms), and peyote (a cactus containing mescaline) are all classified in Schedule I on findings that they lack accepted medical use and cannot be used safely even with professional oversight.

Peyote carries one significant carve-out the others do not. Federal law explicitly protects the use, possession, and transportation of peyote by Native Americans for bona fide traditional ceremonial purposes connected to the practice of a traditional Indian religion.³ DEA regulations reinforce this by stating that peyote’s Schedule I listing does not apply to nondrug use in bona fide religious ceremonies of the Native American Church, and church members using peyote in that context are exempt from DEA registration.⁴ Anyone who manufactures or distributes peyote to the church still has to register with the DEA annually. LSD and psilocybin have no comparable federal exemptions. Some states and cities have created local frameworks that deprioritize enforcement or allow supervised therapeutic use, but those policies do not change federal law, and federal prosecution remains possible.

MDMA

MDMA (commonly called Ecstasy or Molly) is a synthetic drug that acts as both a stimulant and a hallucinogen. The DEA classifies it in Schedule I on findings of high abuse potential, no accepted medical use, and a lack of accepted safety under supervision.⁵ MDMA drew significant attention as a potential treatment for post-traumatic stress disorder, but in August 2024 the FDA declined to approve MDMA-assisted therapy, issuing a Complete Response Letter that asked for a new clinical trial to better assess durability and safety. As of mid-2026, MDMA remains in Schedule I with no approved therapeutic application.

Marijuana (Mostly)

Marijuana’s Schedule I status has been the most contested classification in the system for decades, and it changed in a limited way in April 2026. The Justice Department moved two categories of marijuana products into Schedule III: FDA-approved drug products containing marijuana, and marijuana products held under a qualifying state medical marijuana license.⁶

All other marijuana remains Schedule I. Recreational marijuana, black-market marijuana, and any marijuana not covered by a state medical license or FDA approval still carry full Schedule I penalties at the federal level.⁷ The DEA scheduled an administrative hearing beginning June 29, 2026, on whether to reschedule all marijuana from Schedule I to Schedule III. That proceeding has not concluded.⁶

Federal Penalties

Simple possession of any Schedule I substance, without intent to distribute, carries up to one year in prison and a minimum $1,000 fine for a first offense. A second offense raises the ceiling to two years and a $2,500 minimum fine. A third or subsequent conviction can mean up to three years and a $5,000 minimum fine.⁸

Distribution penalties climb sharply with weight. For heroin, distributing 100 grams or more of a mixture triggers a five-year mandatory minimum with a 40-year maximum. At one kilogram or more, the mandatory minimum jumps to 10 years with a possible life sentence. Fines can reach $10 million for an individual defendant and $50 million for an organization on first offenses at the highest tier. A prior serious drug felony doubles those caps.⁹

The Analogue Act: Unlisted Drugs That Still Count

Schedule I is not limited to substances the statute names. Under 21 U.S.C. § 813, any “controlled substance analogue” intended for human consumption is treated as a Schedule I drug for purposes of federal criminal law.¹⁰ The provision targets designer drugs and synthetic knockoffs whose chemists tweak the molecular structure just enough to sidestep the official list.

A substance qualifies as a controlled substance analogue if it is chemically similar to a Schedule I or II drug and either produces similar stimulant, depressant, or hallucinogenic effects on the central nervous system or is represented as producing those effects. To decide whether a substance was intended for human consumption, courts look at how it was marketed and labeled, whether the labeled purpose had any legitimate use, pricing compared to the substance it mimicked, and whether the defendant knew it was meant to be ingested, inhaled, or injected. Labeling a product “not for human consumption” is not by itself enough to defeat an analogue prosecution; the statute says that evidence alone cannot establish that a substance was not intended for consumption. That language closed the loophole that sellers of synthetic cannabinoids and bath salts exploited for years.

Research Restrictions

Studying a Schedule I substance is legal but requires far more paperwork and physical security than working with drugs in lower schedules. Every researcher needs a separate DEA registration specifically authorizing Schedule I work, obtained through DEA Form 225. The application must include a detailed research protocol, and changes to the protocol (new drugs, different quantities, amended procedures) require a formal modification through the DEA.¹¹

Storage rules are strict. Practitioner-researchers must keep Schedule I substances in a securely locked, substantially constructed cabinet. Non-practitioner facilities, such as pharmaceutical manufacturers, must use a qualifying safe or a purpose-built vault, with reinforced concrete walls, alarm systems tied to a central monitoring station or police, and doors rated to resist forced and surreptitious entry for specified time periods.¹² The total amount of any Schedule I substance that can be manufactured in the United States each year is also capped by an aggregate production quota the DEA publishes annually.¹³ Importing or exporting a Schedule I substance requires a shipment-specific DEA permit.¹⁴

How Drugs Get Added, Removed, or Moved

The DEA holds the final authority to schedule, reschedule, or decontrol substances under 21 U.S.C. § 811, working from the binding scientific and medical evaluation prepared by HHS. Anyone can start the process. Any person may petition the DEA to change a substance’s classification by submitting five copies of a petition to the Administrator, along with a concise statement of the facts, a summary of relevant medical or scientific evidence, and the specific rule change sought. The DEA must respond within a reasonable time, either accepting the petition for filing or explaining why it was rejected.¹⁵

Emergency Scheduling

When a new substance poses an immediate public safety threat and the normal process would take too long, the Attorney General can place it in Schedule I temporarily without full rulemaking. This emergency power under 21 U.S.C. § 811(h) requires a finding of “imminent hazard to the public safety” based on factors like actual abuse, diversion from legitimate channels, and clandestine manufacturing. A temporary order lasts two years and can be extended by one additional year if permanent scheduling proceedings are underway.² The DEA has used this power repeatedly against synthetic drugs. In 2018 the agency temporarily scheduled an entire class of fentanyl-related substances rather than listing individual chemicals one by one, and that class-wide order has been extended multiple times by Congress as permanent scheduling legislation has stalled.

State Schedules Can Differ From Federal

Every state maintains its own controlled substance schedules, and they do not always mirror the federal list. Most states adopted some version of the Uniform Controlled Substances Act, but alignment varies. Some states automatically incorporate federal changes; others require independent legislative or administrative action. A drug can be Schedule I federally and classified differently, or not scheduled at all, under state law, and vice versa.

States also frequently impose stricter research, dispensing, and labeling rules than federal law. First-offense possession penalties under state law can range from probation to several years in prison, with fines from a few thousand dollars to $25,000 or more depending on the jurisdiction. Because state and federal schedules can diverge, activity that is legal under one system may still violate the other. Checking both before assuming any substance is lawful to possess, distribute, or research is the only safe approach.

1
Office of the Law Revision Counsel. 21 USC 812 – Schedules of Controlled Substances
2
Office of the Law Revision Counsel. 21 USC 811 – Authority and Criteria for Classification of Substances
3
Office of the Law Revision Counsel. 42 USC 1996a – Traditional Indian Religious Use of Peyote
4
eCFR. 21 CFR 1307.31 – Native American Church
5
Drug Enforcement Administration. Ecstasy/MDMA Drug Fact Sheet
6
Department of Justice. Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to State Medical Marijuana Licenses in Schedule III
7
Department of Justice. Schedules of Controlled Substances – Rescheduling of FDA-Approved Products Containing Marijuana
8
Office of the Law Revision Counsel. 21 USC 844 – Penalties for Simple Possession
9
Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A
10
Office of the Law Revision Counsel. 21 USC 813 – Treatment of Controlled Substance Analogues
11
DEA Diversion Control Division. Schedule I Controlled Substances Research Information
12
eCFR. 21 CFR Part 1301 – Physical Security Controls for Storage Areas
13
eCFR. 21 CFR Part 1303 – Quotas
14
eCFR. 21 CFR Part 1312 – Importation and Exportation of Controlled Substances
15
eCFR. 21 CFR 1308.43 – Initiation of Proceedings for Rulemaking